Beyond DNA repair: the novel immunological potential of PARP inhibitors

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Loss of excision repair cross-complementation group 1 (ERCC1) is common in lung cancer.
• Mutations in breast cancer type 1/2 susceptibility genes (BRCA1/2) are prevalent in ovarian, breast, and prostate cancers.
• ERCC1 loss or BRCA1/2 mutations confer sensitivity to poly-(ADP-ribose) polymerase inhibitors (PARPi).

Purpose of the Study:

• To investigate the impact of PARPi on anti-tumor immunity in ERCC1- or BRCA-defective cancers.
• To explore the potential of PARPi in potentiating anti-tumor immune responses.

Main Methods:

• Analysis of tumor cell-autonomous immune phenotypes in ERCC1- or BRCA-defective contexts.
• Review of existing research on PARPi effects in cancer models.

Main Results:

• PARPi selectively trigger tumor cell-autonomous immune phenotypes in ERCC1- or BRCA-defective settings.
• PARPi demonstrate the potential to enhance anti-tumor immunity.

Conclusions:

• PARPi may exert therapeutic effects by potentiating anti-tumor immunity.
• PARPi could be a valuable therapeutic option for selected patient populations with ERCC1- or BRCA-defective cancers.